{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:49:50Z","timestamp":1782103790828,"version":"3.54.5"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,21]]},"DOI":"10.7759\/cureus.111259","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:39:47Z","timestamp":1782103187000},"source":"Crossref","is-referenced-by-count":0,"title":["Pre-exposure Prophylaxis Outcomes in High-Risk Individuals in Saudi Arabia: A 48-Week Observational Cohort Study"],"prefix":"10.7759","author":[{"given":"Ali","family":"Alsaeed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2174\/18746136-v17-230420-2022-15","article-title":"Public awareness and stigmatizing attitudes toward people living with human immunodeficiency virus acquired immune deficiency syndrome in Saudi Arabia","author":"Alwazzeh MJ","year":"2023","unstructured":"Alwazzeh MJ, Kabbani A, Alghamdi M, et al.. Public awareness and stigmatizing attitudes toward people living with human immunodeficiency virus acquired immune deficiency syndrome in Saudi Arabia. Open AIDS J. 2023, 17. 10.2174\/18746136-v17-230420-2022-15","journal-title":"Open AIDS J"},{"key":"ref2","unstructured":"HIV and AIDS Geneva | WHO. (2025). Accessed. March 19, 2026: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hiv-aids."},{"key":"ref3","unstructured":"Global HIV & AIDS statistics \u2014 fact sheet | UNAIDS. (2024). Accessed. March 19, 2026: https:\/\/www.unaids.org\/en\/resources\/fact-sheet."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(22)00100-X","article-title":"HIV incidence and impact of interventions among female sex workers and their clients in the Middle East and north Africa: a modelling study","volume":"9","author":"Chemaitelly H","year":"2022","unstructured":"Chemaitelly H, Ayoub HH, Omori R, El Feki S, Hermez JG, Weiss HA, Abu-Raddad LJ. HIV incidence and impact of interventions among female sex workers and their clients in the Middle East and north Africa: a modelling study. Lancet HIV. 2022, 9:e496-505. 10.1016\/S2352-3018(22)00100-X","journal-title":"Lancet HIV"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1177\/09564624251346055","article-title":"Call to action: a roadmap for HIV prevention and PrEP adoption in the Gulf region","volume":"37","author":"AlHammadi AA","year":"2026","unstructured":"AlHammadi AA, Alharbi A, Subhi A, et al.. Call to action: a roadmap for HIV prevention and PrEP adoption in the Gulf region. Int J STD AIDS. 2026, 37:4-13. 10.1177\/09564624251346055","journal-title":"Int J STD AIDS"},{"key":"ref6","unstructured":"Ending the AIDS epidemic among young people in the Middle East and  North Africa. Advocacy report | UNICEF Middle East and North Africa Regional Office. (2024). Accessed: March 19, 2026: https:\/\/www.unicef.org\/mena\/reports\/ending-aids-epidemic-among-young-people?utm_source=copilot.com."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-016-1286-4","article-title":"An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis","volume":"17","author":"Dolling DI","year":"2016","unstructured":"Dolling DI, Desai M, McOwan A, et al.. An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxis. Trials. 2016, 17:163. 10.1186\/s13063-016-1286-4","journal-title":"Trials"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-048478","article-title":"Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations","volume":"12","author":"O Murchu E","year":"2022","unstructured":"O Murchu E, Marshall L, Teljeur C, Harrington P, Hayes C, Moran P, Ryan M. Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations. BMJ Open. 2022, 12:e048478. 10.1136\/bmjopen-2020-048478","journal-title":"BMJ Open"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1011205","article-title":"Preexposure chemoprophylaxis for HIV prevention in men who have sex with men","volume":"363","author":"Grant RM","year":"2010","unstructured":"Grant RM, Lama JR, Anderson PL, et al.. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010, 363:2587-99. 10.1056\/NEJMoa1011205","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2408591","article-title":"The real PURPOSE of PrEP - effectiveness, not efficacy","volume":"391","author":"Walensky RP","year":"2024","unstructured":"Walensky RP, Baden LR. The real PURPOSE of PrEP - effectiveness, not efficacy. N Engl J Med. 2024, 391:1246-7. 10.1056\/NEJMe2408591","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1108524","article-title":"Antiretroviral prophylaxis for HIV prevention in heterosexual men and women","volume":"367","author":"Baeten JM","year":"2012","unstructured":"Baeten JM, Donnell D, Ndase P, et al.. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012, 367:399-410. 10.1056\/NEJMoa1108524","journal-title":"N Engl J Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(17)30089-9","article-title":"Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study","volume":"4","author":"Molina JM","year":"2017","unstructured":"Molina JM, Charreau I, Spire B, et al.. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017, 4:402-10. 10.1016\/S2352-3018(17)30089-9","journal-title":"Lancet HIV"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25883","article-title":"Increasing awareness of HIV pre-exposure prophylaxis (PrEP) and willingness to use HIV PrEP among men who have sex with men: a systematic review and meta-analysis of global data","volume":"25","author":"Sun Z","year":"2022","unstructured":"Sun Z, Gu Q, Dai Y, et al.. Increasing awareness of HIV pre-exposure prophylaxis (PrEP) and willingness to use HIV PrEP among men who have sex with men: a systematic review and meta-analysis of global data. J Int AIDS Soc. 2022, 25:e25883. 10.1002\/jia2.25883","journal-title":"J Int AIDS Soc"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.80842","article-title":"A systematic literature review on pre-exposure prophylaxis as a strategy for HIV risk reduction in the Middle East","volume":"17","author":"Chaponda M","year":"2025","unstructured":"Chaponda M, AlHammadi AA, Alsaeed A, Ali B, Al Salman J, Alosaimi RS. A systematic literature review on pre-exposure prophylaxis as a strategy for HIV risk reduction in the Middle East. Cureus. 2025, 17:e80842. 10.7759\/cureus.80842","journal-title":"Cureus"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-10153-1","article-title":"Sexually transmitted infections in the middle east and North Africa: comprehensive systematic review and meta-analysis","volume":"24","author":"Obeid D","year":"2024","unstructured":"Obeid D, Alsuwairi F, Alnemari R, et al.. Sexually transmitted infections in the middle east and North Africa: comprehensive systematic review and meta-analysis. BMC Infect Dis. 2024, 24:1229. 10.1186\/s12879-024-10153-1","journal-title":"BMC Infect Dis"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-40743-z","article-title":"Trends and projection of incidence, mortality, and disability-adjusted life years of HIV in the Middle East and North Africa (1990-2030)","volume":"13","author":"Khorrami Z","year":"2023","unstructured":"Khorrami Z, Balooch Hasankhani M, Khezri M, Jafari-Khounigh A, Jahani Y, Sharifi H. Trends and projection of incidence, mortality, and disability-adjusted life years of HIV in the Middle East and North Africa (1990-2030). Sci Rep. 2023, 13:13859. 10.1038\/s41598-023-40743-z","journal-title":"Sci Rep"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31065-5","article-title":"Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial","volume":"396","author":"Mayer KH","year":"2020","unstructured":"Mayer KH, Molina JM, Thompson MA, et al.. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020, 396:239-54. 10.1016\/S0140-6736(20)31065-5","journal-title":"Lancet"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(22)00004-2","article-title":"Kidney function in tenofovir disoproxil fumarate-based oral pre-exposure prophylaxis users: a systematic review and meta-analysis of published literature and a multi-country meta-analysis of individual participant data","volume":"9","author":"Schaefer R","year":"2022","unstructured":"Schaefer R, Amparo da Costa Leite PH, Silva R, et al.. Kidney function in tenofovir disoproxil fumarate-based oral pre-exposure prophylaxis users: a systematic review and meta-analysis of published literature and a multi-country meta-analysis of individual participant data. Lancet HIV. 2022, 9:e242-53. 10.1016\/S2352-3018(22)00004-2","journal-title":"Lancet HIV"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000000647","article-title":"Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm","volume":"29","author":"Haberer JE","year":"2015","unstructured":"Haberer JE, Bangsberg DR, Baeten JM, et al.. Defining success with HIV pre-exposure prophylaxis: a prevention-effective adherence paradigm. AIDS. 2015, 29:1277-85. 10.1097\/QAD.0000000000000647","journal-title":"AIDS"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20053844","article-title":"An evolving HIV epidemic in the Middle East and North Africa (MENA) region: a scoping review","volume":"20","author":"Karbasi A","year":"2023","unstructured":"Karbasi A, Fordjuoh J, Abbas M, et al.. An evolving HIV epidemic in the Middle East and North Africa (MENA) region: a scoping review. Int J Environ Res Public Health. 2023, 20:10.3390\/ijerph20053844","journal-title":"Int J Environ Res Public Health"},{"key":"ref21","article-title":"Sampling Techniques","author":"Cochran WG","year":"1997","unstructured":"Cochran WG. Sampling Techniques. John Wiley & Sons, Inc, Hoboken; 1997."},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1506273","article-title":"On-demand preexposure prophylaxis in men at high risk for HIV-1 infection","volume":"373","author":"Molina JM","year":"2015","unstructured":"Molina JM, Capitant C, Spire B, et al.. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015, 373:2237-46. 10.1056\/NEJMoa1506273","journal-title":"N Engl J Med"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad507","article-title":"HIV prevention among men who have sex with men: tenofovir alafenamide combination preexposure prophylaxis versus placebo","volume":"229","author":"Zivich PN","year":"2024","unstructured":"Zivich PN, Cole SR, Edwards JK, et al.. HIV prevention among men who have sex with men: tenofovir alafenamide combination preexposure prophylaxis versus placebo. J Infect Dis. 2024, 229:1123-30. 10.1093\/infdis\/jiad507","journal-title":"J Infect Dis"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00056-2","article-title":"Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial","volume":"387","author":"McCormack S","year":"2016","unstructured":"McCormack S, Dunn DT, Desai M, et al.. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016, 387:53-60. 10.1016\/S0140-6736(15)00056-2","journal-title":"Lancet"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1402269","article-title":"Tenofovir-based preexposure prophylaxis for HIV infection among African women","volume":"372","author":"Marrazzo JM","year":"2015","unstructured":"Marrazzo JM, Ramjee G, Richardson BA, et al.. Tenofovir-based preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2015, 372:509-18. 10.1056\/NEJMoa1402269","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(21)00071-0","article-title":"Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Ogbuagu O","year":"2021","unstructured":"Ogbuagu O, Ruane PJ, Podzamczer D, et al.. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet HIV. 2021, 8:e397-407. 10.1016\/S2352-3018(21)00071-0","journal-title":"Lancet HIV"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1202614","article-title":"Preexposure prophylaxis for HIV infection among African women","volume":"367","author":"Van Damme L","year":"2012","unstructured":"Van Damme L, Corneli A, Ahmed K, et al.. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012, 367:411-22. 10.1056\/NEJMoa1202614","journal-title":"N Engl J Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(22)00030-3","article-title":"Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis","volume":"9","author":"Zhang J","year":"2022","unstructured":"Zhang J, Li C, Xu J, et al.. Discontinuation, suboptimal adherence, and reinitiation of oral HIV pre-exposure prophylaxis: a global systematic review and meta-analysis. Lancet HIV. 2022, 9:e254-68. 10.1016\/S2352-3018(22)00030-3","journal-title":"Lancet HIV"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.2947","article-title":"Association of HIV preexposure prophylaxis with incidence of sexually transmitted infections among individuals at high risk of HIV infection","volume":"321","author":"Traeger MW","year":"2019","unstructured":"Traeger MW, Cornelisse VJ, Asselin J, et al.. Association of HIV preexposure prophylaxis with incidence of sexually transmitted infections among individuals at high risk of HIV infection. JAMA. 2019, 321:1380-90. 10.1001\/jama.2019.2947","journal-title":"JAMA"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-05651-2","article-title":"On-demand oral pre-exposure prophylaxis with tenofovir\/emtricitabine: what every clinician needs to know","volume":"35","author":"Saberi P","year":"2020","unstructured":"Saberi P, Scott HM. On-demand oral pre-exposure prophylaxis with tenofovir\/emtricitabine: what every clinician needs to know. J Gen Intern Med. 2020, 35:1285-8. 10.1007\/s11606-020-05651-2","journal-title":"J Gen Intern Med"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70847-3","article-title":"Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study","volume":"14","author":"Grant RM","year":"2014","unstructured":"Grant RM, Anderson PL, McMahan V, et al.. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014, 14:820-9. 10.1016\/S1473-3099(14)70847-3","journal-title":"Lancet Infect Dis"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25420","article-title":"Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate - emtricitabine for HIV pre-exposure prophylaxis","volume":"23","author":"Liegeon G","year":"2020","unstructured":"Liegeon G, Antoni G, Pialoux G, et al.. Changes in kidney function among men having sex with men starting on demand tenofovir disoproxil fumarate - emtricitabine for HIV pre-exposure prophylaxis. J Int AIDS Soc. 2020, 23:e25420. 10.1002\/jia2.25420","journal-title":"J Int AIDS Soc"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf221","article-title":"Bone changes with long-acting cabotegravir or tenofovir disoproxil fumarate\/emtricitabine for HIV prevention in cisgender men and transgender women: HPTN 083","volume":"81","author":"Brown TT","year":"2025","unstructured":"Brown TT, Arao RF, Warsi M, et al.. Bone changes with long-acting cabotegravir or tenofovir disoproxil fumarate\/emtricitabine for HIV prevention in cisgender men and transgender women: HPTN 083. Clin Infect Dis. 2025, 81:983-6. 10.1093\/cid\/ciaf221","journal-title":"Clin Infect Dis"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw765","article-title":"Decline in bone mass with tenofovir disoproxil fumarate\/emtricitabine is associated with hormonal changes in the absence of renal impairment when used by HIV-uninfected adolescent boys and young men for HIV preexposure prophylaxis","volume":"64","author":"Havens PL","year":"2017","unstructured":"Havens PL, Stephensen CB, Van Loan MD, et al.. Decline in bone mass with tenofovir disoproxil fumarate\/emtricitabine is associated with hormonal changes in the absence of renal impairment when used by HIV-uninfected adolescent boys and young men for HIV preexposure prophylaxis. Clin Infect Dis. 2017, 64:317-25. 10.1093\/cid\/ciw765","journal-title":"Clin Infect Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/488603-pre-exposure-prophylaxis-outcomes-in-high-risk-individuals-in-saudi-arabia-a-48-week-observational-cohort-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:39:59Z","timestamp":1782103199000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/488603-pre-exposure-prophylaxis-outcomes-in-high-risk-individuals-in-saudi-arabia-a-48-week-observational-cohort-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,21]]},"references-count":34,"URL":"https:\/\/doi.org\/10.7759\/cureus.111259","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,21]]}}}